Health Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Accelr8 Technology Corporation
Accelr8 and BD Sign Research and Licensing Option Agreement for Commercializing Accelr8's BACcel Rapid Diagnostics Technology
June 6th, 2008
Accelr8 Technology Corporation (AMEX: AXK) announced that it has signed an agreement with BD (Becton, Dickinson and Company) with respect to Accelr8's BACcel(TM) rapid pathogen diagnostics platform. Under the agreement, BD will fund a research program at Accelr8 through September 30, 2009. The research program includes mutually agreed milestones to support BD's product development planning. BD has the option, during or at the conclusion of the research program, to exclusively license Accelr8's intellectual property in the field of infectious diseases diagnostics. Accelr8 would retain the right to commercialize its technology for other applications. The option, if...
Source: Health Business Week (2008-06-06)
|
